WAM
NVLN

Wolverine Asset Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Wolverine Asset Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,400
Closed -$87K – 1487
2016
Q4 		$87K Buy
+10,400
New +$92.1K ﹤0.01% 948

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Wolverine Asset Management's NVLN Position: Q1 2017 in Review

Wolverine Asset Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2017, closing a stake of 2,739 shares — an estimated $23K sold.

Wolverine Asset Management first reported a position in NVLN in Q4 2016 and held it in 1 quarter. The position peaked at $23K in Q4 2016. 66 funds tracked by Wall St. Rank hold NVLN as of Q1 2017.

  • Wolverine Asset Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2017 after selling out during the quarter.
  • Wolverine Asset Management sold 2,739 Novelion Therapeutics Inc. Common Shares shares in Q1 2017, an estimated $23K.
  • Wolverine Asset Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 1 quarter.
  • Wolverine Asset Management's Novelion Therapeutics Inc. Common Shares position peaked at $23K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2017.

Based on Wolverine Asset Management's 13F filing for Q1 2017, filed 15 May 2017.